-
Mashup Score: 1Evolution of low HER2 expressions between primary and metastatic breast cancer | OncologyPRO - 3 year(s) ago
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Latest advances in breast cancer research - 4 year(s) ago
Serafin Morales, PhD, University Hospital Arnau de Vilanova, Lleida, Spain, discusses the latest advances in breast cancer research. Specifically mentioned…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Loss of HER2 after neoadjuvant treatment of HER2+ early BC - 4 year(s) ago
Serafin Morales, PhD, University Hospital Arnau de Vilanova, Lleida, Spain, discusses the loss of HER2 after neoadjuvant treatment of HER2+…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cabo alone or with trast for BC with brain mets? - 4 year(s) ago
Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, talks on whether is it better to use cabozantinib (cabo)…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Walter P. Weber, MD, PhD, of Basel University Hospital, Basel, Switzerland, discusses the Phase III TAXIS trial (NCT03513614) which aims…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Targeting low HER2 expression with antibody-drug conjugates - 4 year(s) ago
Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, discusses low HER2 expression metastatic breast cancer and its treatment with…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Remarkable data: trastuzumab deruxtecan for HER2+ BC - 4 year(s) ago
Sandra Swain, MD, FACP, Georgetown University Medical Center, Washington, DC, discusses the use of trastuzimab direxican for the treatment of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, discusses tumor mutational burden and PTEN alterations as molecular correlates…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Serafin Morales, PhD, of the University Hospital Arnau de Vilanova, Lleida, Spain, discusses how genetic tools can guide personalized medicine…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cabo alone or with trast for BC with brain mets? - 4 year(s) ago
Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, talks on whether is it better to use cabozantinib (cabo)…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
RT @PTarantinoMD: Working on it! 🏗 https://t.co/Xvm8myVHvu #ESMOBreast20 @myESMO https://t.co/GuofJTb1gR